FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:2080-2081 December 19, 2002 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Herbrecht, R. PubMed Citation

To the Editor: Herbrecht et al. (Aug. 8 issue)¹ show the superiority of voriconazole over amphotericin B for primary therapy of invasive aspergillosis. However, we are concerned about the striking difference in the duration of treatment: a median of 10 days with amphotericin B, as compared with 77 days with voriconazole. How can one be so sure that "the superiority of voriconazole . . . was not the result of excessive interruptions" of amphotericin B? First, the use of one of the lipid formulations of amphotericin B, which are tolerated better by the kidneys than amphotericin B deoxycholate,² would probably . . . [Full Text of this Article]

This article has been cited by other articles:

• Ament, A. J. H. A., Hubben, M. W. A., Verweij, P. E., de Groot, R., Warris, A., Donnelly, J. P., Wout, J. v. t, Severens, J. L. (2007). Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 60: 385-393 [Abstract] [Full Text]